Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide

Qin-Shu Shao, Zai-Yuan Ye, Zhi-Qiang Ling, Jin-Jing Ke

Abstract

AIM: To investigate the effect of arsenic trioxide on human gastric cancer cell line MKN45 with respect to both cytotoxicity and induction of apoptosis in vitro.

METHODS: MKN45 cells were treated with arsenic trioxide (As$_2$O$_3$) at the concentration of 1, 5, and 10 µmol/L, respectively, for three successive days. Cell growth and proliferation were observed by cell counting and trypan blue exclusion. Cytotoxicity of As$_2$O$_3$ was determined by MTT assay. Morphologic changes were studied with light microscopy. Flow cytometry was used to assay cell DNA distribution and apoptotic cells were confirmed with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and DNA electrophoresis.

RESULTS: The growth of MKN45 cells was significantly inhibited by As$_2$O$_3$ which was confirmed by colony-forming assay. After 7 d of culture with various concentrations of As$_2$O$_3$, colony-forming capacity of MKN45 cells decreased with As$_2$O$_3$ increment in comparison with that of control group. The inhibitory rate of colony-formation was 38.5%, 99.1%, and 99.5% when the concentration of As$_2$O$_3$ was 1, 5, and 10 µmol/L in culture medium, respectively. The number of a single colony in drug treatment groups was less than that of control group. The cell-killing rate of As$_2$O$_3$ to MKN45 cells was both dose- and time-dependent with an IC$_{50}$ of (11.05±0.25) µmol/L. After incubation in 10 µmol/L As$_2$O$_3$ for 24 h, the cell-killing rate was 27.1%, and it was close to 50% after 48 h. The results showed that As$_2$O$_3$ induced time- and dose-dependent apoptosis in MKN45 cells, blocked at G$_2$/M phase. The apoptotic peak (sub-G$_1$ phase) appeared and cell apoptotic rate in MKN45 cells was 18.3-32.5% after treatment by 10 µmol/L As$_2$O$_3$ for 48 h. The percentage of G$_2$/M cell of the experimental groups was 2.0-5.0 times than that of the control group. Gel electrophoresis of DNA from cells treated with each concentration of As$_2$O$_3$ for 48 h revealed a “ladder” pattern, indicating preferential DNA degradation at the internucleosomal, linker DNA sections. TUNEL also demonstrated strand breaks in DNA of MKN45 cells treated with As$_2$O$_3$, while control cells showed negative labeling.

CONCLUSION: As$_2$O$_3$ can induce apoptosis of human gastric carcinoma cells MKN45, which is the basis of its effectiveness. It shows great potential in the treatment of gastric carcinoma.

INTRODUCTION

Arsenic trioxide (As$_2$O$_3$) is a major ingredient of traditional Chinese medicine (TCM). It is derived from Pi’shi by sublimation. In the practice of TCM, it is used externally to cure hemorrhoids, acute ulcerative gingivitis, and asthma, etc. Its anti-tumor activity was discovered by a group of Chinese doctors in 1970s[11-14]. Since then, the effect of As$_2$O$_3$ in treating cancers has been extensively studied. The first use of As$_2$O$_3$ in cancer therapy was to treat acute promyelocytic leukemia (APL). Both the results of in vitro and clinical trials showed that As$_2$O$_3$ was effective in inhibiting the growth of APL. Because of the significant anti-cancer effect of As$_2$O$_3$, studies were carried out on its potential use in cancer treatment of non-APL such as myeloid leukemia, hepatocellular carcinoma, neuroblastoma, esophageal carcinoma as well as head and neck cancers. Reports showed that As$_2$O$_3$ was also effective in inhibiting the growth of these cancers[15-19].

Gastric cancer is one of the most common malignant tumors in China. Evidences have demonstrated that gastric cancer is a disease caused not only by excessive cellular proliferation and poor differentiation, but also by decrease in apoptosis of gastric cells[12,14-19]. Though the disease in its early stage can be treated by surgical resection, in advanced stage its response to conventional chemotherapy or radiotherapy is usually not satisfactory. Moreover, surgical resection and radiotherapy are carried out provided that...
the cancer is restricted to a particular region. However, cancer may metastasize to other regions at the later stage of cancer development. For chemotherapy, side effects like toxic hepatitis and heart damage may result. Moreover, prolonged treatment with anticancer drugs may give rise to multidrug-resistant cancer cells, which in turn, poses great obstacle in cancer therapy. Therefore, discovery of new drugs for the treatment of gastric cancer is urgent. Apoptosis is an important mode of cell death that occurs in response to a variety of agents including ionizing radiation or anticancer chemotherapeutic drugs\[20-24\].

In the present study, the effects of \(\text{As}_2\text{O}_3\) on human gastric cancer cell line, MKN45, was investigated by in vitro study.

**MATERIALS AND METHODS**

**Cell culture and drug treatment**

Poorly differentiated human gastric adenocarcinoma cell line, MKN45, was grown in RPMI 1640 (Gibco BRL, Life Technologies, Inc., Rockville, MD, USA) supplemented with 2 mol/L L-glutamine, 10% heat-inactivated fetal bovine serum (FBS, Gibco BRL, Life Technologies, Inc.) and 5% mixture of 100 U/mL penicillin, 100 \(\mu\)g/mL streptomycin, 0.25 \(\mu\)g/mL amphotericin B (Antibiotic-Antimycotic, Gibco BRL, Life Technologies, Inc.). After being subcultured for 24 h, exponentially growing cell suspensions were distributed into 25-cm\(^2\) cell culture flasks at a density of 5\(\times\)10\(^5\) cells/mL (5 mL medium). Cells were passaged twice weekly, routinely examined for mycoplasma contamination, and maintained in 37°C incubator in a humidified atmosphere consisting of 50 mL/L CO\(_2\) in air.

\(\text{As}_2\text{O}_3\) (Sigma Chemical, St. Louis, MO, USA) was dissolved in PBS at 1 mol/L as a stock solution, stored at 4°C. For in vitro use, the stock solution was diluted to the appropriate concentration in growth medium without FBS. Exponentially growing cells were treated with \(\text{As}_2\text{O}_3\) at a final concentration of 1, 5, 10 \(\mu\)mol/L respectively. Control cultures were treated with distilled PBS at a final concentration of 0.1% in culture medium. All experiments were performed in triplicate.

**Cell growth and proliferation assay**

The proliferation of MKN45 cells during the period of experiments was monitored by counting cell number, IC\(_{50}\) and mitotic indices. Cell suspension was mixed with equal volume of 0.08% trypan blue solution (Sigma Chemical Co., Ltd, St. Louis, MO, USA). The mixture was then transferred to the hemacytometer. Only viable cells (unstained cells) were counted.

Inhibition rate of cell growth (%) = [viable control cells-viable treated cells]/viable control cells\(\times\)100%.

To avoid possible influence of cell density on cell growth and survival, cells were maintained at less than 1\(\times\)10\(^5\)/mL with daily adjustment by addition of fresh culture medium containing the corresponding concentration of \(\text{As}_2\text{O}_3\).

**Colony-forming assays**

To assess effects of \(\text{As}_2\text{O}_3\) on MKN45 cell lines, exponentially growing cells at a density of 5\(\times\)10\(^5\) cells/mL (5 mL medium) were mixed with RPMI 1640 supplemented with 2 mol/L L-glutamine, 20% heat-inactivated fetal bovine serum and 5% mixture of 100 U/mL penicillin, 100 \(\mu\)g/mL streptomycin, 0.25 \(\mu\)g/mL amphotericin B. One microliter of liquid culture was plated in a 35-mm plastic culture plate in the presence of various concentrations of \(\text{As}_2\text{O}_3\), and maintained in 37°C incubator in a humidified atmosphere containing 50 mL/L CO\(_2\) in air. After 7 d, more than 40 colony formation in methylcellulose was assessed by inverted phase-contrast microscopy. All experiments were performed in triplicate.

**MTT cytotoxicity assay**

In vitro growth inhibition effect of \(\text{As}_2\text{O}_3\) on MKN45 cells was determined by measuring MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) dye absorbance of living cells. Briefly, cells (1\(\times\)10\(^5\) cells per well) were seeded in 96-well microtiter plates (Nunc, Roskilde, Denmark). After exposure to various \(\text{As}_2\text{O}_3\) for 48 and 72 h respectively, 100 \(\mu\)L (1 g/L) MTT (Sigma) solution was added to each well and the plates were incubated for an additional 4 h at 37°C. MTT solution in medium was aspirated. To achieve solubilization of the formazan crystal formed in viable cells, 100 \(\mu\)L DMSO was added to each well before absorbance at 570 nm was measured. Each concentration treatment was done in triplicate wells. The cytotoxicity rates were measured by the formula:

the cytotoxicity rate=\([1-\text{A}_{\text{MTT test}}/\text{A}_{\text{MTT control}}]\)\(\times\)100%.

**Morphologic assessment of apoptosis by light microscopy and DAPI staining**

Following exposure to \(\text{As}_2\text{O}_3\), cells were obtained, washed with PBS, cytopun onto slides, and stained with Wright-Giemsa for morphologic assessment of apoptosis by light microscopy. Evidence of apoptosis was indicated by the presence of cell shrinkage, membrane blebbing, fragmentation of nuclei, and formation of apoptotic bodies. Apoptosis was also detected by DAPI (Sigma) as previously described, and the percentages of cells in interphase, mitosis, and apoptosis were quantified.

**Cell cycle analysis**

Cell cycle and apoptotic cells were detected by flow cytometry which was performed as described previously. After drug treatment, about 1\(\times\)10\(^6\) cells at each time point were collected by trypsin digestion and centrifugation, then fixed in 70% ethanol/PBS for at least 12 h at 4°C. After 100 \(\mu\)L (1 g/L) RNase treatment, cells were stained with 50 mg/L propidium iodide. Cells were examined by flow cytometry using an FACScan (FACS-420, USA). Also, in cell cycle analysis, cells were considered to be in apoptosis if they exhibited sub-G\(_1\) DNA fluorescence and a forward angle light scatter, the same as or slightly lower than that of cells in G\(_0\). The results were analyzed with Lysis II software (FACS-420, USA).

**DNA gel electrophoresis**

A total of 1\(\times\)10\(^6\) cells with or without \(\text{As}_2\text{O}_3\) treatment were gently scraped from the dishes and washed twice in cold PBS. The pellets were collected by centrifugation and
resuspended in 1 mL of buffer containing 150 μmol/L NaCl, 10 mol/L Tris-HCl pH 8.0, 20 mol/L EDTA pH 8.0, and 0.5% SDS. After thorough mixing, 20 μL of proteinase K (10 mg/mL) was added and incubated at 50 °C for 2 h and cooled to 0 °C, 2 mL of ethanol (at -20 °C) was added to precipitate DNA, which was collected by centrifugation (1 200 r/min, 20 min), dried in air and dissolved in 50 μL of 10 mol/L Tris, 1 mol/L EDTA at pH 8.0 (TE buffer).

Each DNA preparation was mixed with 2 mL RNase (10 μmol/L Tris, 1 mol/L EDTA at pH 8.0 (TE buffer). Each DNA preparation was mixed with 2 mL RNase (10 μmol/L Tris, 1 mol/L EDTA at pH 8.0 (TE buffer).

The assay was performed after exposure of exponentially growing MKN45 cells to As2O3, which was confirmed by colony-forming assay. After 7 d of culture with various concentrations of As2O3, colony-forming capacity of MKN45 cells decreased with As2O3 increment in comparison with that of control group. The inhibitory rate of colony forming was 38.5%, 99.1%, and 99.5% when the concentration of As2O3 was 1, 5, and 10 μmol/L in culture medium, respectively. The cell number of a single colony in drug treatment groups was less than that of control group.

**Effect of As2O3 on colony formation of MKN45 cells**

The growth of MKN45 cells was significantly inhibited by As2O3, which was confirmed by colony-forming assay. After 7 d of culture with various concentrations of As2O3, colony-forming capacity of MKN45 cells decreased with As2O3 increment in comparison with that of control group. The inhibitory rate of colony forming was 38.5%, 99.1%, and 99.5% when the concentration of As2O3 was 1, 5, and 10 μmol/L in culture medium, respectively. The cell number of a single colony in drug treatment groups was less than that of control group.

**Effect of As2O3 on MKN45 cells**

The cell-killing rate of As2O3 on MKN45 cells was significant as revealed by MTT, and was both dose- and time-dependent. After incubation in 1 μmol/L As2O3 for 24 h, the cell-killing rate was 11.5%, and after treatment with 10 μmol/L As2O3 for 48 h, the cell-killing rate was close to 50% (Table 2). These results indicated that the cytotoxic effect of As2O3 was strong.

**Morphologic changes of MKN45 cells**

By inverted phase-contrast microscopy, we found that the attaching ability of MKN45 cells to the flask treated with 1, 5, and 10 μmol/L As2O3 was weaker as compared with that of controls, and cell growth markedly inhibited.

MKN45 cells treated with As2O3 underwent significant changes as seen under microscope, the nucleocytoplasmic ratio enlarged, with indentation of nuclei. The nucleocytoplasmic ratio in MKN45 cells treated with 1 μmol/L As2O3 was much smaller than that in controls, and the nuclei appeared round, with loss of nuclear indentation, but with well-differentiated organelles in the cytoplasm. When treated with As2O3 at 5 and 10 μmol/L for three successive days, one could find intact cell membrane, nuclear condensation and apoptotic body formation, but much less than in 1 μmol/L As2O3 group.

**Effect of As2O3 on cell cycle of MKN45 cells**

The effect of As2O3 on MKN45 cells showed remarkable cell cycle specificity. There was no significant change in cell cycle after 1-10 μmol/L treatment for 24 h, being similar to control group. The fraction of G1/G2 decreased from 55.6%, 57.1%, 55.2% to 37.2%, 19.9%, 13.1% after 1, 5, 10 μmol/L treatment for 48 h, respectively, while the...
fraction of G₂/M phase was increased from 16.3%, 16.7%, 17.5% to 22.6%, 41.5%, 69.0%, respectively.

The results showed that As₂O₃ induced time- and dose-dependent apoptosis in MKN45 cells, blocked at G₂/M phase. The apoptotic peak (sub-G₁ phase) appeared and cell apoptotic rate was 18.3-32.5% after being treated by 10 µmol/L As₂O₃ for 48 h (Tables 3 and 4). The percentage of G₂/M cells of the experimental groups was 2.0-5.0 times that of the control group. It demonstrated that As₂O₃ arrested cell cycle at G₂/M phase, inhibited cell proliferation and induced apoptosis at G₁ phase.

**Table 3** Effect of As₂O₃ on apoptosis of MKN45 cells

| Groups            | Apoptosis (%) |
|-------------------|---------------|
|                   | 24 h | 48 h | 72 h |
| Control           | 0.5±1.1 | 0.4±0.3 | 0.5±0.2 |
| As₂O₃ (µmol/L)    |      |      |      |
| 1                 | 2.7±2.1a | 7.3±2.5a | 12.3±3.6a |
| 5                 | 7.3±5.7a | 17.3±5.7a | 21.1±5.6a |
| 10.0              | 11.6±3.4a | 25.4±7.1a | 35.8±8.1a |

*P<0.05 vs control.

**Gel electrophoresis**

Gel electrophoresis of DNA from cells treated with each concentration of As₂O₃ for 48 h revealed a “ladder” pattern, indicating preferential DNA degradation at the internucleosomal, linker DNA sections.

**TUNEL assay**

TUNEL assay also demonstrated strand breaks in DNA of MKN45 cells treated with As₂O₃, while control cells showed negative labeling.

**DISCUSSION**

The medicinal effect of As₂O₃ is of great significance, though it is also well known for its toxicity. As₂O₃ has been used as medicine for thousands of years in both the Chinese and Western societies. However, its use in cancer treatment was not discovered until 1970[1-3]. Since then, As₂O₃ has been found to be an effective anticancer drug in APL as well as non-APL leukemia[4-6,16-18]. Recently, studies were carried out to expand the use of As₂O₃ in the treatment of solid tumors. The present study explored its effect on human gastric cancer cell line.

As₂O₃ has been used in clinical trials of APL for years and 10 mg/d of As₂O₃ was shown to be effective in inducing complete remission of both the newly diagnosed and relapsed APL patients. The action mechanism of As₂O₃ is complicated. In APL, it has been reported that As₂O₃ exerted its effect by degradation of the fusion protein, PML/RARα, in turn, inducing differentiation and triggering apoptosis. This was supported by clinical trials. However, some studies showed that As₂O₃ mediated its effect in a PML/RARα independent manner. This suggested that the effect of PML/ RARα is not restricted to cancers which express PML/ RARα[24-27,31]. In fact, apoptosis is one of the key pathways of As₂O₃, regardless of cell types. Studies showed that caspase-3 is activated upon As₂O₃ treatment. Caspases can be considered as the central trigger of apoptosis because they bring about most of the visible changes that characterize apoptotic cell death. Among various caspases, caspase-3 is one of the most crucial caspases[28-32,34].

Mitochondria play an important role in apoptosis. As₂O₃ causes the collapse of mitochondrial membrane potential, indicating that mitochondria participate in As₂O₃-induced apoptosis. Disruption of the mitochondrial membrane potential and release of cytochrome c to the cytosol can be considered as the major event through which mitochondria participate in the induction of apoptosis. The change in the mitochondrial membrane potential upon As₂O₃ treatment was examined by flow cytometry, while the release of cytochrome c to the cytosol was detected by Western analysis. As₂O₃ recruits a number of pathways but the whole picture of its action mechanism is not fully understood[35-39].

The present study showed that As₂O₃ exhibited strong anticancer activity on MKN45 cells via inhibition of proliferation and induction of apoptosis, which was both dose- and time-dependent in a certain range of dose with an IC₅₀ of (11.05±0.25) µmol/L. The apoptosis rate was increased 3.5 times when the concentration of As₂O₃ increased from 1 to 10 µmol/L. Gel electrophoresis of DNA and TUNEL demonstrated existence of apoptotic cells. Flow cytometry analysis showed that the apoptotic peak (sub-G₁ phase) changed considerably with the increase of concentration of As₂O₃ and, cell were blocked at G₂/M phase. The effect of As₂O₃ on cell cycle was obvious, while no distinct changes occurred in cell cycle treatment by different concentrations of As₂O₃ for 24 h being similar to control group. However, the cell cycle changed markedly after drug treatment for 48 h, G₂/M phase decreased from 55.6%, 57.1%, 55.2% to 37.2%, 19.9%, 13.1% and the G₂/M phase increased from 16.3%, 16.7%, 17.5% to 22.6%, 41.5%, 69.0% in 1, 5, 10 µmol/L As₂O₃ treatment groups, respectively. The arrest of G₂/M phase become more

**Table 4** Effect of As₂O₃ on cell cycle of MKN45 cells

| Group            | Cell cycle (%) |
|------------------|---------------|
|                  | 24 h | 48 h | 72 h |
|                  | G₂/M | S   | G₂/M |
|                  |      |     |      |
| Control          | 54.5 | 25.8 | 19.7 |
| As₂O₃ (µmol/L)  |      |      |      |
| 1                | 55.6 | 28.1 | 16.3 |
| 5                | 57.1 | 26.2 | 16.7 |
| 10.0             | 55.2 | 27.3 | 17.5 |
| 1                | 56.7 | 30.1 | 13.2 |
| 5                | 37.2 | 40.2 | 22.6 |
| 10.0             | 13.1 | 17.9 | 69.0 |

*P<0.05 vs control.
apparent after treatment with As$_2$O$_3$ for 72 h, its proportion increased with the increase of concentration of As$_2$O$_3$ in a dose- and time-dependent manner. The proportion of cells in G$_2$/M phase was 2.0-5.0 times that of untreated cells after treatment with As$_2$O$_3$ for 48 h, demonstrating that the antitumor effect of As$_2$O$_3$ on MKN45 cells was attributed to the inhibition of cell proliferation, arrest of cell cycle and induction of apoptosis.

In conclusion, our study demonstrates the proliferation inhibition and apoptosis induction effects of As$_2$O$_3$ at the concentrations of 1, 5, and 10 µmol/L on human gastric cancer cell line MKN45. These results shed light on the use of As$_2$O$_3$ in treating human gastric cancer. To fully utilize As$_2$O$_3$ in cancer treatment, however, much more efforts should be made on the study of its action mechanism, pharmacokinetic characteristics, dosing schedules as well as potential adverse effects.

REFERENCES

1. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004; 28: 891-900
2. Candoni A, Silvestri F, Buonamici S, Li D, Reddy P, Gallili N, Nuñofora G, Raza A. Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 2004; 41: 13-20
3. Sun Y, Kim SH, Zhou DC, Ding W, Paletta E, Guidize F, Zelent A, Ramesh KH, Cannizzaro L, Warrell RP, Gallagher RE. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia 2004; 18: 1258-1269
4. Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004; 5: 389-401
5. Gao F, Yi J, Yuan JQ, Shi GY, Tang XM. The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 2004; 14: 81-85
6. Rousselet P, Larghero J, Labaume S, Poupol J, Chopin M, Dosquet C, Marleau JP, Janin A, Brouet JC, Femand JP. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72: 166-171
7. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YM. Arsenic trioxide growth inhibition in MC/CA MYELOMA cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071
8. Miller WH, Chipper HM, Lee JS, Singer J, Saxman W. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
9. Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemend-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PML/RARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193: 531-543
10. Iwama K, Nakajo S, Aiuchi T, Nakaya K. Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca$^{2+}$-dependent production of superoxide. Int J Cancer 2001; 92: 518-526
11. Maeda H, Hori S, Nishihot H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432-5440
12. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230-235
13. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, Kim BK. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001; 18: 249-255
14. Davison K, Mann KK, Waxman S, Miller WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004; 103: 3496-3502
15. Liang XQ, Cao EH, Zhang Y, Qin JF. F35-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells. Oncol Rep 2003; 10: 1265-1269
16. Kang YJ. New understanding in cardiotoxicity. Curr Opin Drug Discov Devel 2003; 6: 110-116
17. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098-4104
18. Peng CQ, Ma WL, Zheng WL. Research advances on effect of arsenic trioxide on tumor. Aizheng 2002; 21: 1386-1389
19. Huang SG, Kong BH, Ma YY, Jiang S. Impact of arsenic trioxide on proliferation and metastasis of drug-resistant human ovarian carcinoma cell line. Aizheng 2002; 21: 863-867
20. Miller WH Jr, Chipper HM, Lee JS, Singer J, Saxman W. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
21. Tsimberidou AM, Estey E, Whitman CJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994
22. Shen Z, Li S, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng FZ, Yan H, Liu YF, Chen Y, Shen Y, Wu T, Wang T, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid (13-cis-retinoic acid)/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukaemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335
23. Lu D, Bai XC, Gui L, Su YC, Deng F, Liu B, Li XM, Zeng WS, Cheng BL, Luo SQ. Hydrogen peroxide in the Burkitt’s lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway. Br J Haematol 2004; 125: 512-520
24. Karlsson J, ORA I, Porn-Ares I, Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004; 10: 3179-3188
25. Chelbi-alik MK, Bobe B, Benoit G, Canova A, Pine R. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 2003; 22: 9121-9130
26. Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. PLoS Med 2003; 27: 174-179
27. Kang SH, Song JH, Kang HK, Kang JH, Kim SJ, Kang HW, Lee YK, Park DB. Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. Exp Mol Med 2003; 35: 83-90
28. Hu XM, Hirano T, Oka K. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother Pharmacol 2003; 52: 47-58
29. Jia P, Chen G, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L, Yu Y, Chen S, Zhang X, Wang Z. Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chin Med J (Engl) 2001; 114: 19-24
30. Akay C, Thomas C, Gazetti Y. Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle 2004; 3: 324-334
31. Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, Almasan A,
Tang H, Chen Q. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. *Oncogene* 2004; 23: 1239-1247

McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. *Mol Cancer Ther* 2003; 2: 1155-1164

Akay C, Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. *Cell Cycle* 2003; 2: 358-368

Lecureur V, Le Thiec A, Le Meur A, Amiot L, Drenou B, Bernard M, Lamy T, Fauchet R, Fardel O. Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells. *Br J Haematol* 2002; 119: 608-615

Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. *Mol Cancer Ther* 2003; 2: 711-719

Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Walmire CN, Coon A, Dorr RT. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. *Mol Cancer Ther* 2002; 1: 185-195

Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). *J Invest Dermatol* 2003; 121: 881-893

Choi YJ, Park JW, Suh SI, Mun KC, Bae JH, Song DK, Kim SP, Kwon TK. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. *Int J Oncol* 2002; 21: 603-610

Sordet O, Rebe C, Leroy I, Bruey JM, Garrido C, Miquet C, Lizard G, Plenchette S, Corcos L, Solary E. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. *Blood* 2001; 97: 3931-3940